Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$56.04 USD

56.04
285,706

-0.28 (-0.50%)

Updated Aug 28, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

by Zacks Equity Research

Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.

    Geron Stock Rises after Positive Interim Update on Imetelstat

    by Zacks Equity Research

    Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.

      Arpita Dutt headshot

      Forget Novartis, Buy These Two Pharma Stocks Instead

      by Arpita Dutt

      With Novartis (NVS) being a Zacks Rank #4 (Sell) stock, here is a look at two European pharma stocks that sport a strong Zacks Rank.

        Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk

        by Zacks Equity Research

        A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control

          Arpita Dutt headshot

          Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?

          by Arpita Dutt

          Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.

            Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

            by Zacks Equity Research

            Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

              VIVUS to Regain Commercial Rights for Stendra from Sanofi

              by Zacks Equity Research

              VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.

                Arpita Dutt headshot

                Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved

                by Arpita Dutt

                This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.

                  Joseph Lu headshot

                  Flexion (FLXN) Stock Soars 35% on $1 Billion Sanofi Buyout

                  by Joseph Lu

                  Shares of Flexion Therapeutics (FLXN) soared on Thursday, up 36% to $26.80 per share following reports that French drug giant Sanofi (SNY) is in talks to purchase the biotech company for more than $1 billion in cash.

                    Merck Closes Acquisition of Controlling Stake in Vallee S.A

                    by Zacks Equity Research

                    Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.

                      Will Sanofi (SNY) Prove to be a Suitable Value Stock?

                      by Zacks Equity Research

                      Value investing is easily one of the most popular ways to find great stocks in any market environment.

                        Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop

                        by Zacks Equity Research

                        Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.

                          What are Sanofi's (SNY) Strengths and Challenges in 2017?

                          by Zacks Equity Research

                          We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.

                            Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat

                            by Zacks Equity Research

                            We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.

                              Amgen's Repatha Meets Primary Endpoint in Phase III Study

                              by Zacks Equity Research

                              Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).

                                Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays

                                by Zacks Equity Research

                                We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.

                                  Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?

                                  by Zacks Equity Research

                                  Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.

                                    Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates

                                    by Zacks Equity Research

                                    Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.

                                      Ionis Pharma Lipid Disorder Candidate Positive in Phase III

                                      by Zacks Equity Research

                                      Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.

                                        Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M

                                        by Zacks Equity Research

                                        Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.

                                          Arpita Dutt headshot

                                          5 FDA Decisions to Watch Out for in Mar 2017

                                          by Arpita Dutt

                                          Companies like Merck (MRK) are awaiting key FDA decisions this month.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug

                                            by Arpita Dutt

                                            Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.

                                              Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                                              by Zacks Equity Research

                                              Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                                                BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat

                                                by Zacks Equity Research

                                                BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.

                                                  Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More

                                                  by Zacks Equity Research

                                                  The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.